CA3128826A1 - Compositions et procedes pour detecter une maladie gastro-intestinale - Google Patents

Compositions et procedes pour detecter une maladie gastro-intestinale Download PDF

Info

Publication number
CA3128826A1
CA3128826A1 CA3128826A CA3128826A CA3128826A1 CA 3128826 A1 CA3128826 A1 CA 3128826A1 CA 3128826 A CA3128826 A CA 3128826A CA 3128826 A CA3128826 A CA 3128826A CA 3128826 A1 CA3128826 A1 CA 3128826A1
Authority
CA
Canada
Prior art keywords
iap
nec
activity
protein
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3128826A
Other languages
English (en)
Inventor
Sunyoung Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/267,120 external-priority patent/US11493515B2/en
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of CA3128826A1 publication Critical patent/CA3128826A1/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/195—Antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)

Abstract

La présente invention concerne des compositions et des procédés pour détecter et traiter des maladies gastro-intestinales.
CA3128826A 2019-02-04 2020-02-04 Compositions et procedes pour detecter une maladie gastro-intestinale Pending CA3128826A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/267,120 US11493515B2 (en) 2016-08-04 2019-02-04 Compositions and methods to detect gastrointestinal disease
US16/267,120 2019-02-04
PCT/US2020/016646 WO2020163381A1 (fr) 2019-02-04 2020-02-04 Compositions et procédés pour détecter une maladie gastro-intestinale

Publications (1)

Publication Number Publication Date
CA3128826A1 true CA3128826A1 (fr) 2020-08-13

Family

ID=83366685

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3128826A Pending CA3128826A1 (fr) 2019-02-04 2020-02-04 Compositions et procedes pour detecter une maladie gastro-intestinale

Country Status (5)

Country Link
EP (1) EP3920713A4 (fr)
CN (2) CN120102879A (fr)
AU (1) AU2020217717B2 (fr)
CA (1) CA3128826A1 (fr)
WO (1) WO2020163381A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114113624A (zh) * 2020-08-28 2022-03-01 香港城市大学深圳研究院 利用免疫球蛋白关联蛋白质组开发疾病标志物的方法及装置

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11741686B2 (en) 2020-12-01 2023-08-29 Raytheon Company System and method for processing facility image data
WO2023141560A2 (fr) * 2022-01-20 2023-07-27 Synthetic Biologics, Inc. Phosphatase alcaline destinée à être utilisée en oncologie
CN116662798B (zh) * 2023-04-23 2026-02-24 迪辅乐生物(上海)有限公司 基于肠型分型的微生物组合物、过敏预测模型的构建方法及其模型和应用
WO2025075652A1 (fr) * 2023-10-06 2025-04-10 DeLorean Artificial Intelligence, Inc. Système et méthode de gestion de soins médicaux
CN120673884B (zh) * 2025-08-20 2025-11-04 温州医科大学 基于ai的克林霉素磷酸酯加工水解优化方法及系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026383A2 (fr) * 2004-08-26 2006-03-09 Strategic Health Decisions, Inc. Systeme pour optimiser les strategies de traitement au moyen d'un systeme d'evaluation specifique du patient
US20140162370A1 (en) * 2011-06-14 2014-06-12 The Board Of Trustees Of The Leland Stanford Junior University Urine biomarkers for necrotizing enterocolitis and sepsis
US10950353B2 (en) * 2013-09-20 2021-03-16 Georgia Tech Research Corporation Systems and methods for disease progression modeling
BR112017014419A2 (pt) * 2015-01-09 2018-01-16 S Malo Madhu diagnose e tratamento de diabetes incipiente
WO2018027179A1 (fr) * 2016-08-04 2018-02-08 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions et méthodes pour détecter une maladie gastro-intestinale
CN108061556B (zh) * 2017-10-18 2021-07-09 广州傲胜机器人科技有限公司 一种基于隐马尔可夫模型的地图匹配方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114113624A (zh) * 2020-08-28 2022-03-01 香港城市大学深圳研究院 利用免疫球蛋白关联蛋白质组开发疾病标志物的方法及装置

Also Published As

Publication number Publication date
CN113645846B (zh) 2025-02-25
CN113645846A (zh) 2021-11-12
CN120102879A (zh) 2025-06-06
EP3920713A4 (fr) 2022-11-09
EP3920713A1 (fr) 2021-12-15
AU2020217717B2 (en) 2026-03-12
WO2020163381A1 (fr) 2020-08-13
AU2020217717A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
CA3128826A1 (fr) Compositions et procedes pour detecter une maladie gastro-intestinale
US11493515B2 (en) Compositions and methods to detect gastrointestinal disease
Heath et al. Association of intestinal alkaline phosphatase with necrotizing enterocolitis among premature infants
EP2350662B1 (fr) Combinaison des facteurs de risque cardiovasculaire oxpl/apob et d'activité spla2 pour le diagnostic/pronostic d'une maladie/d'un événement cardiovasculaire
Mori et al. Prognostic implications of the global leadership initiative on malnutrition criteria as a routine assessment modality for malnutrition in hospitalized patients at a university hospital
US20150132771A1 (en) Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
US20250222077A1 (en) Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury
Coll et al. Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease
US9417247B2 (en) Human autoantibodies specific for PAD3 which are cross-reactive with PAD4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases
US11953501B2 (en) Compositions and methods to detect gastrointestinal disease
US20230258660A1 (en) A method for distinguishing healthy individuals from individuals having infectious or inflammatory conditions
Canisso et al. Use of a qualitative horse-side test to measure serum amyloid A in mares with experimentally induced ascending placentitis
US20240393333A1 (en) Compositions and methods to detect gastrointestinal disease
US12282019B2 (en) Compositions and methods to detect gastrointestinal disease
MXPA04005919A (es) Metodo analitico para detectar efingomielinasa alcalina y kit para uso en este metodo.
Sharif et al. Assessing physicians’ perspectives on determinants of endoscopy decisions in children exposed to non-pharmacological corrosive agent: insights from poison control center
Waqqar et al. Redox imbalance correlates with high Nugent score in bacterial vaginosis
Bindi et al. Evaluation of oxidative stress and antioxidant defense biomarkers in healthy and colic horses: correlation with type of colic and outcome
Tayman et al. A Pilot Study on the Dual Role of ADAMTS-1,-4, and-5 in Necrotizing Enterocolitis: Linking Tissue Pathology and Serum Biomarker Discovery
Muzammil et al. Exocrine pancreatic insufficiency in systemic diseases: unravelling the complex interplay–a comprehensive review
JP2025078980A (ja) 間質性肺炎症急性増悪患者における肺線維化進行のリスクを予測するためのバイオマーカー
Hoskin Neutrophil activation in inflammatory bowel disease
Yakob Associations between oral biofilm, periodontal disease, and systemic health: with a focus on atherosclerosis and breast cancer
Yakob Associations between oral biofilm, periodontal disease, and systemic health
Harry Cridge et al. Top Questions About Pancreatitis in Dogs

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240126

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250131

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250131

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250131

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250212

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250612

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260130

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260130